Biological agents in monotherapy for the treatment of rheumatoid arthritis

Biological agents in monotherapy for the treatment of rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease, which results in joint destruction and permanent disability. The advent of disease-modifying antirheumatic drugs (DMARDs) has made a profound impact on the outcome and prognosis of RA. Methotrexate (MTX) is a central agent in...

Full description

Bibliographic Details
Main Authors: Cem Gabay, Paul Hasler, Diego Kyburz, Alexander So, Peter Villiger, Johannes von Kempis, Ulrich Walker
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2014-04-01
Series:Swiss Medical Weekly
Subjects:
tocilizumab
rheumatoid arthritis
TNFα
IL-6
DMARDs
monotherapy
Online Access:https://www.smw.ch/index.php/smw/article/view/1856

Internet

https://www.smw.ch/index.php/smw/article/view/1856

Similar Items